Table 2 Recommended therapy management after index event

No antiplatelet therapy

9 (4.2%)

 With OAC monotherapy

6

OAC + ASA

3 (4.2%)

 Without temporal recommendation

OAC + Clopidogrel

1 (1.4%)

 With temporal recommendation for 3 months

Monotherapy antiplatelet:

28 (38.9%)

 ASA

25 (34.7%)

  Without temporal recommendation

24

  With temporal recommendation for 3 months

1

 Clopidogrel

2 (2.8%)

  Without temporal recommendation

1

  With temporal recommendation for 6 months

1

 Ticagrelor

1 (1.4%)

  With temporal recommendation for 12 months

1

Dual antiplatelet therapy:

29 (40.3%)

 ASA + Clopidogrel

24 (33.3%)

  Without temporal recommendation

5

  With temporal recommendation:

19

   1 month

2

   3 months

4

   6 months

4

   12 months

8

 ASA + Prasugrel

2 (2.8%)

  Without temporal recommendation

1

  With temporal recommendation for 12 months

1

 ASA + Ticagrelor

3 (4.2%)

  Without temporal recommendation

0

  With temporal recommendation

3

   1 month

1

   3 months

1

   12 months

1

 “Triple” therapy with ASA

2 (2.8%)

  1 month, Clopidogrel + OAC 6 months, OAC monotherapy

1

  1 month, Clopidogrel + OAK 12 months, OAC monotherapy

1